Signal Opportunity · Strategic initiative
IMVIONIX Launches With Novartis's BEOVU, Taking Over Retina Drug Marketing in U.S. and Canada
- Location
- Peachtree Corners, Georgia
- Industry
- Biotech
- Employees
- Not stated
- Opportunity type
- Strategic initiative
What happened
On November 10, 2026, IMVIONIX Inc., a privately held ophthalmology company in Peachtree Corners, Georgia, announced it had acquired exclusive U.S. and Canadian commercial rights to the retinal therapy BEOVU (brolucizumab-dbll) from Novartis. The deal is the company's first transaction and its official commercial launch. IMVIONIX will become the marketing authorization holder in both countries. Financial terms were not disclosed.
BEOVU is an FDA-approved intravitreal injection for wet age-related macular degeneration and diabetic macular edema. IMVIONIX was founded in 2025 by the former executive team of Alimera Sciences, with backing from Caligan Partners and Velan Capital. Its plan is to give proven retinal drugs more focused attention from a company dedicated to retina specialists. Moving a brand from Novartis to a new owner means the company now has to build its own commercial presence, physician outreach and brand communications. BEOVU is still a Novartis trademark used under license.
Relevant services
- Brand & creative
- Digital marketing
- PR & communications
- Web & app
Overview
IMVIONIX is a privately held biotechnology company focused on retinal therapies. It finds, develops and commercializes treatments for retina patients and the specialists who treat them. The company was founded in 2025 by former Alimera Sciences executives, in collaboration with Caligan Partners LP and Velan Capital. Its first commercial product is BEOVU, which it markets in the United States and Canada.
Why this could be interesting
- A new commercial company relaunching a drug needs brand, HCP marketing and communications.
Best suited for: A healthcare and pharma marketing agency.
Summary by Agency Field Guide from public reporting. Nobody has asked for proposals; this is a reason to reach out, not an invitation to bid.